Last reviewed · How we verify
Dato-DXd
Dato-DXd is an antibody-drug conjugate that targets TROP-2 on cancer cells and delivers a DNA-damaging payload (deruxtecan) to induce cell death.
Dato-DXd is an antibody-drug conjugate that targets TROP-2 on cancer cells and delivers a DNA-damaging payload (deruxtecan) to induce cell death. Used for Metastatic or unresectable gastric cancer, Metastatic or unresectable biliary tract cancer, Non-small cell lung cancer (NSCLC).
At a glance
| Generic name | Dato-DXd |
|---|---|
| Also known as | DS-1062a, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Datopotamab Deruxtecan, IMP administration, DS-1062 |
| Sponsor | AstraZeneca |
| Drug class | Antibody-drug conjugate (ADC) |
| Target | TROP-2 (Trophoblast cell surface antigen 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Dato-DXd combines a humanized monoclonal antibody against TROP-2 (a tumor-associated antigen) with a topoisomerase I inhibitor payload (deruxtecan). Upon binding to TROP-2 on cancer cells, the conjugate is internalized and the payload is released intracellularly, causing DNA damage and apoptosis. The linker technology allows controlled release of the cytotoxic agent specifically within tumor cells.
Approved indications
- Metastatic or unresectable gastric cancer
- Metastatic or unresectable biliary tract cancer
- Non-small cell lung cancer (NSCLC)
Common side effects
- Neutropenia
- Anemia
- Nausea
- Fatigue
- Diarrhea
- Interstitial lung disease
Key clinical trials
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (PHASE3)
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (PHASE3)
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (PHASE3)
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (PHASE2)
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (PHASE2, PHASE3)
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer (PHASE3)
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) (PHASE3)
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |